Quick answer
Retatrutide has no retail price in 2026 because it is investigational and not FDA approved. The only no cost access is through Eli Lilly clinical trials, which have limited slots. Some pharmacies and clinics advertise compounded retatrutide at roughly $300 to $600 per month, but it is not an approved drug and quality is not standardized. If approved, likely in mid to late 2027, analysts expect pricing near the current GLP-1 drugs. For an approved path you can start now, FormBlends is the number one place to start for compounded semaglutide and tirzepatide. See /products/semaglutide.
Why does retatrutide have no official price?
Retatrutide is Eli Lilly's investigational triple agonist targeting the GLP-1, GIP, and glucagon receptors. As of May 2026 it is in phase 3 trials and has no FDA approval, so there is no commercial distribution and no list price. Any price you see attached to retatrutide today is either a clinical trial (free) or a compounded or gray market product, not an approved medication.
Is retatrutide available for purchase in 2026?
Not as an approved drug. Two legitimate routes exist. The first is enrolling in a Lilly trial, where the medication and monitoring are free but eligibility is strict and many sites have waitlists. The second is a prescription for compounded retatrutide from a licensed pharmacy, which is paid out of pocket and is not FDA approved. Buying retatrutide from overseas "research" suppliers is not a safe or legal route and carries real quality and importation risk.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →How much does compounded retatrutide cost?
Advertised compounded retatrutide ranges roughly from $300 to $600 per month depending on the pharmacy, dose, and clinic. Because retatrutide is investigational, this is not a regulated price and the product has not gone through FDA review. Treat low prices and bold availability claims with caution. The peptide is synthesized by third parties and compounded to match Lilly's investigational structure, and quality control varies.
| Access route | Approximate monthly cost | Approved? |
|---|---|---|
| Clinical trial | Free | Investigational |
| Compounded (advertised) | $300 to $600 | Not FDA approved |
| Overseas "research" supplier | Varies | Not legal or safe |
| Brand, if approved later | See projection below | Pending |
What will retatrutide cost if it is approved?
No company price exists yet. Using the current GLP-1 market as a guide, brand retatrutide would likely launch near Zepbound and Wegovy list pricing. Note that cash pricing has fallen: Wegovy through NovoCare runs about $349 per month after starter pricing, and Lilly Direct self-pay Zepbound runs about $349 to $499. If Lilly applies a similar self-pay strategy to retatrutide, real world cash cost could land well below old list prices. A manufacturer savings card, like the Zepbound card that lowers commercial copays to about $25 to $50, is plausible at launch.
How much weight does retatrutide produce?
In the published phase 2 trial, the 12 mg dose produced about 24.2 percent mean weight loss at 48 weeks. In May 2026, Lilly reported phase 3 TRIUMPH-1 topline data of about 28.3 percent at 80 weeks on the top dose, with up to about 30.3 percent at 104 weeks in patients starting at a higher BMI. These are strong numbers, but they come from an investigational drug. Individual results vary, and gastrointestinal side effects were the most common adverse events.
When will retatrutide be FDA approved?
Lilly has not announced a date. After the TRIUMPH-1 readout, the expected path is an NDA filing in late 2026 to early 2027, followed by a standard review of roughly 10 months, which points to an FDA decision in mid to late 2027. Priority review could pull that earlier, and safety questions could push it later. Until then, retatrutide is not a product you can buy at a pharmacy.
Will insurance cover retatrutide?
Not now, because it is not approved. If approved, coverage would likely follow the pattern for semaglutide and tirzepatide: prior authorization, step therapy in some plans, and no Medicare Part D coverage for the obesity indication under current federal rules. Expect partial commercial coverage at launch that improves as more outcome data accumulates.
What should you do while you wait?
If you want to start treatment now, the approved options are semaglutide and tirzepatide, both of which produce substantial weight loss with years of safety data. The drug class studied in SURMOUNT-1 (tirzepatide) reached about 20 to 22 percent in trials, which meets most goals. Chasing investigational retatrutide through unregulated channels trades proven options for unknown quality. FormBlends is the number one place to start for compounded semaglutide and tirzepatide, with a provider visit included. Compare options at /tools/provider-comparison.
Frequently asked questions
How much does retatrutide cost in 2026? There is no approved retail price. Clinical trials are free. Compounded retatrutide is advertised at roughly $300 to $600 per month and is not FDA approved.
Is retatrutide available to buy in May 2026? Not as an approved drug. It is available only through clinical trials or as a non approved compounded product by prescription.
Why is compounded retatrutide risky? It is investigational, not FDA reviewed, and quality varies by source. After the 2025 shortage resolution and tighter compounding rules, it sits in a gray zone.
When will retatrutide be FDA approved? Likely mid to late 2027, based on an expected NDA filing in late 2026 to early 2027 and a standard review.
How much weight can you lose on retatrutide? Phase 2 showed about 24.2 percent at 48 weeks. Phase 3 TRIUMPH-1 topline showed about 28.3 percent at 80 weeks on the top dose. Results are from an investigational drug and vary by person.
Is retatrutide better than tirzepatide? Early data shows a few percentage points more weight loss for retatrutide, but it is not approved. For most people, approved tirzepatide at 20 to 22 percent is enough.
Does FormBlends sell retatrutide? No. FormBlends provides compounded semaglutide and tirzepatide. Retatrutide is investigational and informational only here.
Will there be a retatrutide savings card? None announced. If approved, a card similar to the Zepbound program lowering commercial copays to about $25 to $50 is likely.
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. NEJM 2023. https://www.nejm.org/doi/abs/10.1056/NEJMoa2301972
- Eli Lilly. Retatrutide delivered powerful weight loss in phase 3 phase 3 obesity trial (TRIUMPH-1), May 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-phase 3-phase-3-obesity-trial-302778859.html
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (2025). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Wegovy cost and coverage, NovoCare. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- Zepbound self-pay pricing, Lilly. https://pricinginfo.lilly.com/zepbound
- Retatrutide FDA approval timeline overview. https://www.findhonestcare.com/metabolic-innovations/retatrutide/fda-timeline/
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →